ShavetaVinayakMD

Instructor, Medicine - Oncology, Stanford University Medical Center

Dr. Vinayak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2007 - 2010
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
Virginia Commonwealth University School of MedicineClass of 2004

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

PubMed

Clinicopathologic and molecular characterization of low-grade, early-stage, and HER2-positive invasive breast carcinoma.
Natasha Hunter, Lisa Han, Haley Corbin, Eric Q Konnick, William R Gwin 3rd
American Journal of Clinical Pathology. 2025-03-05
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer.
Natasha B Hunter, Lanell M Peterson, Jennifer M Specht, David A Mankoff, Mark Muzi
Breast Cancer Research. 2025-02-17
2 citations
Vaccines for breast cancer prevention: Are we there yet?
Shaveta Vinayak, Denise L Cecil, Mary L Disis
Molecular Aspects of Medicine. 2024-08-01

Lectures

TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. Breast Cancer Immunotherapy: Ca...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Fred Hutch/UW Cancer Consortium Breast Cancer Researchers Receive GrantsNovember 17th, 2022
Research into Targeted Treatments, Better Prediction Models in Breast Cancer FundedNovember 22nd, 2023